132 related articles for article (PubMed ID: 16823927)
1. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus.
Bracci L; Canini I; Venditti M; Spada M; Puzelli S; Donatelli I; Belardelli F; Proietti E
Vaccine; 2006 Apr; 24 Suppl 2():S2-56-7. PubMed ID: 16823927
[TBL] [Abstract][Full Text] [Related]
2. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E
Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645
[TBL] [Abstract][Full Text] [Related]
3. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
4. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
5. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
6. Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF-10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses.
Kimoto T; Mizuno D; Takei T; Kunimi T; Ono S; Sakai S; Kido H
Influenza Other Respir Viruses; 2013 Nov; 7(6):1218-26. PubMed ID: 23710832
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
8. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
[TBL] [Abstract][Full Text] [Related]
9. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model.
Proietti E; Bracci L; Puzelli S; Di Pucchio T; Sestili P; De Vincenzi E; Venditti M; Capone I; Seif I; De Maeyer E; Tough D; Donatelli I; Belardelli F
J Immunol; 2002 Jul; 169(1):375-83. PubMed ID: 12077267
[TBL] [Abstract][Full Text] [Related]
10. Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine.
Asanuma H; Hirokawa K; Uchiyama M; Suzuki Y; Aizawa C; Kurata T; Sata T; Tamura S
Vaccine; 2001 Jul; 19(28-29):3981-9. PubMed ID: 11427274
[TBL] [Abstract][Full Text] [Related]
11. Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.
Ye L; Ohnemus A; Ong LC; Gad HH; Hartmann R; Lycke N; Staeheli P
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511392
[TBL] [Abstract][Full Text] [Related]
12. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
13. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
[TBL] [Abstract][Full Text] [Related]
14. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
15. Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection.
Kusakabe T; Ozasa K; Kobari S; Momota M; Kishishita N; Kobiyama K; Kuroda E; Ishii KJ
Vaccine; 2016 Jun; 34(27):3191-3198. PubMed ID: 27160037
[TBL] [Abstract][Full Text] [Related]
16. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
17. Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.
Ren ST; Zhang XM; Sun PF; Sun LJ; Guo X; Tian T; Zhang J; Guo QY; Li X; Guo LJ; Che J; Wang B; Zhang H
PLoS One; 2017; 12(1):e0169501. PubMed ID: 28052136
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Ji X; Ren Z; Xu N; Meng L; Yu Z; Feng N; Sang X; Li S; Li Y; Wang T; Zhao Y; Wang H; Zheng X; Jin H; Li N; Yang S; Cao J; Liu W; Gao Y; Xia X
Viruses; 2016 Apr; 8(4):115. PubMed ID: 27110810
[TBL] [Abstract][Full Text] [Related]
20. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]